Cost-Consequence Analysis of Three Different Diagnostic Strategies in the First- and Second-Line Treatment of Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. FE. 2018;19(1). doi:10.7175/fe.v19i1.1354